# GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies

> **NCT04937153** · PHASE1 · COMPLETED · sponsor: **Genmab** · enrollment: 18 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** Acasunlimab
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04937153
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-15
- **Primary completion:** 2024-10-01
- **Final completion:** 2024-10-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04937153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04937153, "GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04937153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*